521 related articles for article (PubMed ID: 11452249)
1. Effects of oral administration of ibutamoren mesylate, a nonpeptide growth hormone secretagogue, on the growth hormone-insulin-like growth factor I axis in growth hormone-deficient children.
Codner E; Cassorla F; Tiulpakov AN; Mericq MV; Avila A; Pescovitz OH; Svensson J; Cerchio K; Krupa D; Gertz BJ; Murphy G
Clin Pharmacol Ther; 2001 Jul; 70(1):91-8. PubMed ID: 11452249
[TBL] [Abstract][Full Text] [Related]
2. Oral administration of the growth hormone secretagogue MK-677 increases markers of bone turnover in healthy and functionally impaired elderly adults. The MK-677 Study Group.
Murphy MG; Bach MA; Plotkin D; Bolognese J; Ng J; Krupa D; Cerchio K; Gertz BJ
J Bone Miner Res; 1999 Jul; 14(7):1182-8. PubMed ID: 10404019
[TBL] [Abstract][Full Text] [Related]
3. Treatment with the oral growth hormone secretagogue MK-677 increases markers of bone formation and bone resorption in obese young males.
Svensson J; Ohlsson C; Jansson JO; Murphy G; Wyss D; Krupa D; Cerchio K; Polvino W; Gertz B; Baylink D; Mohan S; Bengtsson BA
J Bone Miner Res; 1998 Jul; 13(7):1158-66. PubMed ID: 9661080
[TBL] [Abstract][Full Text] [Related]
4. Effects of a 7-day treatment with a novel, orally active, growth hormone (GH) secretagogue, MK-677, on 24-hour GH profiles, insulin-like growth factor I, and adrenocortical function in normal young men.
Copinschi G; Van Onderbergen A; L'Hermite-Balériaux M; Mendel CM; Caufriez A; Leproult R; Bolognese JA; De Smet M; Thorner MO; Van Cauter E
J Clin Endocrinol Metab; 1996 Aug; 81(8):2776-82. PubMed ID: 8768828
[TBL] [Abstract][Full Text] [Related]
5. Safety and efficacy of growth hormone (GH) during extended treatment of adult Japanese patients with GH deficiency (GHD).
Chihara K; Kato Y; Kohno H; Takano K; Tanaka T; Teramoto A; Shimatsu A
Growth Horm IGF Res; 2008 Aug; 18(4):307-17. PubMed ID: 18282776
[TBL] [Abstract][Full Text] [Related]
6. Stimulation of the growth hormone (GH)-insulin-like growth factor I axis by daily oral administration of a GH secretogogue (MK-677) in healthy elderly subjects.
Chapman IM; Bach MA; Van Cauter E; Farmer M; Krupa D; Taylor AM; Schilling LM; Cole KY; Skiles EH; Pezzoli SS; Hartman ML; Veldhuis JD; Gormley GJ; Thorner MO
J Clin Endocrinol Metab; 1996 Dec; 81(12):4249-57. PubMed ID: 8954023
[TBL] [Abstract][Full Text] [Related]
7. Is insulin-like growth factor-1 monitoring useful in assessing the response to growth hormone of growth hormone-deficient children?
Lanes R; Jakubowicz S
J Pediatr; 2002 Nov; 141(5):606-10. PubMed ID: 12410186
[TBL] [Abstract][Full Text] [Related]
8. Pharmacodynamic hormonal effects of anamorelin, a novel oral ghrelin mimetic and growth hormone secretagogue in healthy volunteers.
Garcia JM; Polvino WJ
Growth Horm IGF Res; 2009 Jun; 19(3):267-73. PubMed ID: 19196529
[TBL] [Abstract][Full Text] [Related]
9. Diagnosis and growth hormone (GH) therapy in children with GH deficiency: experience in King Chulalongkorn Memorial Hospital, Thailand.
Wacharasindhu S; Supornsilchai V; Aroonparkmongkol S; Srivuthana S
J Med Assoc Thai; 2007 Oct; 90(10):2047-52. PubMed ID: 18041422
[TBL] [Abstract][Full Text] [Related]
10. Insulin-like growth factor-1 and growth hormone (GH) levels in canine cerebrospinal fluid are unaffected by GH or GH secretagogue (MK-0677) administration.
Prahalada S; Block G; Handt L; DeBurlet G; Cahill M; Hoe CM; van Zwieten MJ
Horm Metab Res; 1999; 31(2-3):133-7. PubMed ID: 10226793
[TBL] [Abstract][Full Text] [Related]
11. Free dissociable insulin-like growth factor I (IGF-I), total IGF-I and their binding proteins in girls with Turner syndrome during long-term growth hormone treatment.
Bannink EM; van Doorn J; Stijnen T; Drop SL; de Muinck Keizer-Schrama SM
Clin Endocrinol (Oxf); 2006 Sep; 65(3):310-9. PubMed ID: 16918949
[TBL] [Abstract][Full Text] [Related]
12. MK-677, an orally active growth hormone secretagogue, reverses diet-induced catabolism.
Murphy MG; Plunkett LM; Gertz BJ; He W; Wittreich J; Polvino WM; Clemmons DR
J Clin Endocrinol Metab; 1998 Feb; 83(2):320-5. PubMed ID: 9467534
[TBL] [Abstract][Full Text] [Related]
13. Short-term suppression of elevated growth hormone concentrations following insulin-like growth factor 1 administration in young adults with type 1 diabetes does not alter glomerular filtration or albumin excretion rates.
Williams RM; Yuen K; White D; Mallard B; Dalton RN; Acerini CL; Dunger DB
Clin Endocrinol (Oxf); 2006 Oct; 65(4):439-45. PubMed ID: 16984235
[TBL] [Abstract][Full Text] [Related]
14. A placebo-controlled, double-blind trial of growth hormone treatment in prepubertal children after renal transplant.
Hokken-Koelega AC; Stijnen T; de Jong RC; Donckerwolcke RA; Groothoff JW; Wolff ED; Blum WF; de Muinck Keizer-Schrama SM; Drop SL
Kidney Int Suppl; 1996 Jan; 53():S128-34. PubMed ID: 8771007
[TBL] [Abstract][Full Text] [Related]
15. MK-0677, a potent, novel, orally active growth hormone (GH) secretagogue: GH, insulin-like growth factor I, and other hormonal responses in beagles.
Jacks T; Smith R; Judith F; Schleim K; Frazier E; Chen H; Krupa D; Hora D; Nargund R; Patchett A; Hickey G
Endocrinology; 1996 Dec; 137(12):5284-9. PubMed ID: 8940347
[TBL] [Abstract][Full Text] [Related]
16. The chronic oral administration of arginine aspartate decreases secretion of IGF-1 and IGFBP-3 in healthy volunteers.
Blazejewski S; Georges A; Forest K; Corcuff JB; Abouelfath A; Girodet PO; Kamagate M; Jacquet A; Pillet O; Bordenave L; Moore N
Fundam Clin Pharmacol; 2009 Jun; 23(3):339-44. PubMed ID: 19527301
[TBL] [Abstract][Full Text] [Related]
17. Oral administration of growth hormone (GH) releasing peptide-mimetic MK-677 stimulates the GH/insulin-like growth factor-I axis in selected GH-deficient adults.
Chapman IM; Pescovitz OH; Murphy G; Treep T; Cerchio KA; Krupa D; Gertz B; Polvino WJ; Skiles EH; Pezzoli SS; Thorner MO
J Clin Endocrinol Metab; 1997 Oct; 82(10):3455-63. PubMed ID: 9329386
[TBL] [Abstract][Full Text] [Related]
18. The pharmacokinetics, pharmacodynamics, safety and tolerability following 7 days daily oral treatment with NN703 in healthy male subjects.
Zdravkovic M; Christiansen T; Eliot L; Agersoe H; Thomsen MS; Falch JF; Søgaard B; Ynddal L; Ilondo MM
Growth Horm IGF Res; 2001 Feb; 11(1):41-8. PubMed ID: 11437473
[TBL] [Abstract][Full Text] [Related]
19. Tissue-specific alterations in insulin-like growth factor-I concentrations in response to 3,3',5-triiodo-L-thyronine supplementation in the growth hormone receptor-deficient sex-linked dwarf chicken.
Vasilatos-Younken R; Dunnington EA; Siegel PB; McMurtry JP
Gen Comp Endocrinol; 1997 Jan; 105(1):31-9. PubMed ID: 9000465
[TBL] [Abstract][Full Text] [Related]
20. Growth hormone and insulin-like growth factor binding protein-1 responses to oral glucose in patients with primary hyperparathyroidism.
Díez JJ; Grande C; Méndez J; González-Gancedo P; Iglesias P
Clin Endocrinol (Oxf); 2006 Jul; 65(1):27-34. PubMed ID: 16817815
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
